| Bioactivity | Vazegepant (BHV-3500) hydrochloride is a highly affinity CGRP receptor antagonist (hCGRP Ki= 0.023 nM). Vazegepant hydrochloride is the first intranasal gepant for migraine. Vazegepant hydrochloride may be helpful in effective management of COVID-19 associated pulmonary inflammation[1][2][3]. |
| Target | Ki: 0.023 nM (hCGRP) |
| Name | Vazegepant hydrochloride |
| CAS | 1414976-20-7 |
| Formula | C36H47ClN8O3 |
| Molar Mass | 675.26 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Moreno-Ajona D, et al. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?. Curr Opin Neurol. 2020;33(3):309-315. [2]. Mehta PP, et al. Novel and Evolving Therapies for COVID-19 Related Pulmonary Complications. Am J Med Sci. 2021;361(5):557-566. [3]. Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?. Curr Opin Neurol. 2020;33(3):309-315. [4]. Nazir Noor, et al. A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine. Health Psychol Res. 2022 Jun 28;10(3):35506. |
Vazegepant hydrochloride
CAS: 1414976-20-7 F: C36H47ClN8O3 W: 675.26
Vazegepant (BHV-3500) hydrochloride is a highly affinity CGRP receptor antagonist (hCGRP Ki= 0.023 nM). Vazegepant hydro
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.